image
PetMed Express, Inc. PETS
Healthcare - Medical - Pharmaceuticals - NASDAQ - US
Watchlist
$ 3.41
6.09 %
$ 70.4 M
Market Cap
331.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one PETS stock under the worst case scenario is HIDDEN Compared to the current market price of 3.41 USD, PetMed Express, Inc. is HIDDEN

PETS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one PETS stock under the base case scenario is HIDDEN Compared to the current market price of 3.41 USD, PetMed Express, Inc. is HIDDEN

PETS Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one PETS stock under the best case scenario is HIDDEN Compared to the current market price of 3.41 USD, PetMed Express, Inc. is HIDDEN

PETS Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PETS

image
1M 5%
6M -50%
1Y -13%
3Y -476%
5Y -697%
All
$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
281 M REVENUE
9.42%
Growth Rates
1Year 9.42%
3Years -3.13%
5Years -0.17%
7Years 1.74%
10Years 1.88%
-8.16 M OPERATING INCOME
-470.77%
Growth Rates
1Year -470.77%
3Years -6.77%
5Years -3.31%
7Years -2.85%
10Years -2.57%
-7.46 M NET INCOME
-3203.43%
Growth Rates
1Year -3203.43%
3Years -7.55%
5Years -3.68%
7Years -3.97%
10Years -3.53%
4.32 M OPERATING CASH FLOW
-84.47%
Growth Rates
1Year -84.47%
3Years -52.42%
5Years -37.46%
7Years -28.94%
10Years -10.78%
-40.7 M INVESTING CASH FLOW
-296.39%
Growth Rates
1Year -296.39%
3Years -155.72%
5Years -130.87%
7Years -21.17%
10Years -77.77%
-12.4 M FINANCING CASH FLOW
49.31%
Growth Rates
1Year 49.31%
3Years 18.16%
5Years 10.72%
7Years 3.10%
10Years 0.61%
53 M REVENUE
-11.06%
Growth Rates
1Year 9.42%
3Years -3.13%
5Years -0.17%
7Years 1.74%
10Years 1.88%
-450 K OPERATING INCOME
-81.23%
Growth Rates
1Year -470.77%
3Years -6.77%
5Years -3.31%
7Years -2.85%
10Years -2.57%
-707 K NET INCOME
-30.40%
Growth Rates
1Year -3203.43%
3Years -7.55%
5Years -3.68%
7Years -3.97%
10Years -3.53%
-1.17 M OPERATING CASH FLOW
-15.78%
Growth Rates
1Year -84.47%
3Years -52.42%
5Years -37.46%
7Years -28.94%
10Years -10.78%
-777 K INVESTING CASH FLOW
38.58%
Growth Rates
1Year -296.39%
3Years -155.72%
5Years -130.87%
7Years -21.17%
10Years -77.77%
-1 K FINANCING CASH FLOW
98.59%
Growth Rates
1Year 49.31%
3Years 18.16%
5Years 10.72%
7Years 3.10%
10Years 0.61%
Balance Sheet PetMed Express, Inc.
image
Current Assets 93.6 M
Cash & Short-Term Investments 55.3 M
Receivables 3.28 M
Other Current Assets 35.1 M
Non-Current Assets 76.2 M
Long-Term Investments 5.3 M
PP&E 28.1 M
Other Non-Current Assets 42.8 M
32.55 %20.64 %3.12 %16.53 %25.22 %Total Assets$169.9m
Current Liabilities 72.2 M
Accounts Payable 37 M
Short-Term Debt 459 K
Other Current Liabilities 34.7 M
Non-Current Liabilities 995 K
Long-Term Debt 995 K
Other Non-Current Liabilities 0
50.61 %47.40 %Total Liabilities$73.2m
EFFICIENCY
Earnings Waterfall PetMed Express, Inc.
image
Revenue 281 M
Cost Of Revenue 202 M
Gross Profit 78.6 M
Operating Expenses 86.8 M
Operating Income -8.16 M
Other Expenses -698 K
Net Income -7.46 M
300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)281m(202m)79m(87m)(8m)698k(7m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
27.98% GROSS MARGIN
27.98%
Averages
1Year 27.98%
3Years 28.06%
5Years 28.37%
7Years 30.17%
10Years 30.88%
-2.90% OPERATING MARGIN
-2.90%
Averages
1Year -2.90%
3Years 1.98%
5Years 5.80%
7Years 9.19%
10Years 10.52%
-2.66% NET MARGIN
-2.66%
Averages
1Year -2.66%
3Years 1.43%
5Years 4.22%
7Years 6.86%
10Years 7.40%
-7.72% ROE
-7.72%
Averages
1Year -7.72%
3Years 1.88%
5Years 8.49%
7Years 14.67%
10Years 17.61%
-4.39% ROA
-4.39%
Averages
1Year -4.39%
3Years 2.12%
5Years 7.15%
7Years 12.55%
10Years 15.28%
-9.89% ROIC
-9.89%
Averages
1Year -9.89%
3Years 1.32%
5Years 8.51%
7Years 14.23%
10Years 17.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis PetMed Express, Inc.
image
45m45m40m40m35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -7.46 M
Depreciation & Amortization 7.06 M
Capital Expenditures -4.51 M
Stock-Based Compensation 6.87 M
Change in Working Capital -2.76 M
Others -379 K
Free Cash Flow -194 K
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets PetMed Express, Inc.
image
Wall Street analysts predict an average 1-year price target for PETS of $13.2 , with forecasts ranging from a low of $7 to a high of $20 .
PETS Lowest Price Target Wall Street Target
7 USD 105.28%
PETS Average Price Target Wall Street Target
13.2 USD 288.56%
PETS Highest Price Target Wall Street Target
20 USD 486.51%
Price
Max Price Target
Min Price Target
Average Price Target
20201818161614141212101088664422Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.3 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.401.401.201.201.001.000.800.800.600.600.400.400.200.200.000.000.170.180.190.250.270.270.280.30.30.180.190.20.250.270.280.30.30.30.180.190.20.270.270.280.30.30.30.180.710.190.750.20.790.271.040.271.080.281.110.31.180.31.200.90201520152016201620172017201820182019201920202020202120212022202220232023
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership PetMed Express, Inc.
image
Sold
0-3 MONTHS
200 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.92 K USD 1
Bought
392 K USD 2
0-3 MONTHS
1.4 M USD 1
3-6 MONTHS
852 K USD 2
6-9 MONTHS
41.8 K USD 1
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 5 days ago
PETMED INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating PetMed Express, Inc. on Behalf of PetMed Stockholders and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In PetMed (PETS) To Contact Him Directly To Discuss Their Options globenewswire.com - 6 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of PetMed Express, Inc. (NASDAQ: PETS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm NEWTOWN, Pa., July 07, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving PetMed Express, Inc. (“PetMed”) (NASDAQ: PETS), resulting from allegations of providing potentially misleading business information to the investing public. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K DELRAY BEACH, Fla., July 03, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS) received on July 2, 2025, an expected notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (the “Form 10-K”), with the Securities and Exchange Commission (“SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. globenewswire.com - 2 weeks ago
PETS Investor ALERT: Block & Leviton Investigating PetMed Express For Possible Securities Fraud; Investors Encouraged to Contact the Firm To Potentially Recover Losses BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating PetMed Express, Inc. (Nasdaq: PETS) for potential securities law violations. Investors who have lost money in their PetMed Express investment should contact the firm to learn more about how they might recover those losses. globenewswire.com - 3 weeks ago
PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing DELRAY BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today provided an update on the status of its fourth quarter and FY 2025 results and 10-K filing. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 3 weeks ago
8. Profile Summary

PetMed Express, Inc. PETS

image
COUNTRY US
INDUSTRY Medical - Pharmaceuticals
MARKET CAP $ 70.4 M
Dividend Yield 0.00%
Description PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Contact 420 South Congress Avenue, Delray Beach, FL, 33445 https://www.1800petmeds.com
IPO Date April 26, 1999
Employees 287
Officers Ms. Robyn DElia Chief Financial Officer Mr. Doug Krulik Chief Accounting Officer Ms. Jacqueline Smith Vice President of People Ms. Carla Dodds Chief Marketing Officer Wendy Zalai Corporate Controller & Corporate Secretary Mr. Umesh Sripad Chief Digital & Technology Officer Ms. Sandra Y. Campos President, Chief Executive Officer & Director Ms. Caroline Conegliano Chief Operating Officer